To this end, a recent study found that B16-F10 melanoma cells expressing the model antigen SIY (SIYRYYGL) with IFNGR1 KO or JAK1 KO were immunologically better controlled by immunocompetent hosts; however, when inoculated together with WT tumor cells, these KO cells escaped anti-PD-1 therapy and outgrew WT tumor cells, seemingly contributing to therapeutic resistance to ICBs [106]. This evidence concerns the gene JAK1 and melanoma.